MOTS-c: what it is and what the evidence says
A mitochondrial-derived peptide studied for its relationship with metabolic efficiency, glucose homeostasis, and cellular-energy signaling. It activates AMPK, which helps muscle take up glucose and burn fat as fuel.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Metabolism is not a single lever. Talk about metabolic compounds usually collapses three separate mechanisms into one word. Appetite regulation is one. How well cells respond to insulin is another, and largely independent of the first. Mobilizing stored fat is a third. A compound may act on one and leave the other two untouched, so knowing which one is the difference between understanding a molecule and reciting its name.
What it is studied for
Metabolic efficiency, energy, body composition.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
There are still no published trials in which MOTS-c is administered to people. The human evidence comes from observational studies that measure its levels, which rise with exercise, decline with age, and are lower in type 2 diabetes. An analog, CB4211, had a phase 1 trial in adults with obesity and fatty liver.
The limitation that matters most
The effects on weight, glucose, performance, and bone come from mice and cell cultures. In people, its absorption, the appropriate regimen, and its safety with long-term use remain to be studied.
Regulatory status
Investigational compound, not approved by any agency. The FDA lists it among the substances that may present risks when compounded and states that it has not identified any human exposure data. For anyone who competes, WADA prohibits it at all times, and the 2026 List names it among the AMPK activators (S4.4.1).
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
Evolving research; individual metabolic context matters. If you are on glucose-lowering medication, watch for signs of hypoglycemia, and if you compete, keep in mind that WADA prohibits it at all times.
With insulin resistance, diabetes, or another metabolic condition, and whenever you are on glucose-lowering medication, have a professional assess it before you start and while you are on it.
What this page cannot give you
A reference page can take you this far. You know what MOTS-c is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a Certificate of Completion with a verifiable certificate ID, a Progress Tracker to follow how you are doing, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistancepreclinical Cell Metab · 2015 · PMID 25738459 →
- The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stresspreclinical Cell Metab · 2018 · PMID 29983246 →
- Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humanshuman J Appl Physiol (1985) · 2021 · PMID 34351816 →
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitationreview Front Endocrinol (Lausanne) · 2023 · PMID 36761202 →
- MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseasesreview Int J Mol Sci · 2022 · PMID 36233287 →
- Mitochondrial-derived peptides and exercisereview Biochim Biophys Acta Gen Subj · 2021 · PMID 34520826 →
- MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolismreview Free Radic Biol Med · 2016 · PMID 27216708 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for MOTS-c or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is MOTS-c?
A mitochondrial-derived peptide studied for its relationship with metabolic efficiency, glucose homeostasis, and cellular-energy signaling. It activates AMPK, which helps muscle take up glucose and burn fat as fuel. It is studied within the area of metabolic.
Is there human evidence for MOTS-c?
There are still no published trials in which MOTS-c is administered to people. The human evidence comes from observational studies that measure its levels, which rise with exercise, decline with age, and are lower in type 2 diabetes. An analog, CB4211, had a phase 1 trial in adults with obesity and fatty liver.
Is it approved by any health agency?
Investigational compound, not approved by any agency. The FDA lists it among the substances that may present risks when compounded and states that it has not identified any human exposure data. For anyone who competes, WADA prohibits it at all times, and the 2026 List names it among the AMPK activators (S4.4.1).
What is the dose of MOTS-c?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what MOTS-c is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.